This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Spire Corporation (Nasdaq: SPIR), a global solar company providing capital equipment and turn-key manufacturing lines to produce photovoltaic (PV) modules, announced today it has been awarded a patent for its invention of a nanophotovoltaic (Nano-PV) device which, when applied to biological cells such as cancer, can control and/or limit their growth.
The United States Patent and Trademark Office has issued Spire Corporation U.S. Patent No. 7,955,965 entitled “Nanophotovoltaic Devices.” Spire’s invention provides Nano-PV devices having sizes in a range of about 50 nanometers to about 5 microns, and a method for their fabrication. The devices functionalized to target specific cells and then are selectively activated by light to generate an electrical charge to kill or interfere with cell growth.
Roger G. Little, Chairman, CEO, and co-inventor, said, “This being our third patent issued from our original invention, we have combined our understanding of photovoltaics with our experience in the biomedical field. We are excited to have received this patent and are enthusiastic that it makes an impact in medicine.”
“This patent further strengthens our intellectual property portfolio in our optoelectronic and biomedical market areas. It is a testament to the creativity of our research staff,” concluded Mr. Little.
About Spire CorporationSpire Corporation is a global solar company providing capital equipment and turn-key production lines to manufacture PV modules. To learn more about Spire Corporation, visit
www.SpireCorp.com or email
Certain matters described in this press release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services, as well as other factors described in the Company's Form 10-K and other periodic reports filed with the Securities and Exchange Commission.